Compare GSK plc (GSK) vs Herbalife Nutrition Ltd (HLF) Price & Performance

GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.

The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.

HLF trades at $12.82, up 1.34% today, with a bullish technical signal from moving averages and oscillators. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue has been stable around $5.0B annually, with a net income margin of 4.53% in 2025. Recent news includes a $250 million share repurchase program and a planned CEO transition effective October 31, 2026.

The stock appears undervalued with a P/E of 8.22 and P/S of 0.26, supported by a 53.84% analyst buy rating and a $19.00 consensus price target. Key risks include high debt levels, with total liabilities at $3.53B, and inconsistent earnings performance. Positive cash flow trends in 2026 projections and margin expansion plans offer potential upside, but investor caution is warranted due to ongoing leadership changes and competitive pressures.